R T Morris1, R N Joyrich2, R W Naumann3, N P Shah4, A H Maurer5, H W Strauss6, J M Uszler7, J T Symanowski3, P R Ellis8, W A Harb9. 1. Barbara Ann Karmanos Cancer Institute. Electronic address: rmorris@med.wayne.edu. 2. Detroit Medical Center, Wayne State University, Detroit. 3. Levine Cancer Institute. 4. Charlotte Radiology, Carolinas Medical Center, Charlotte. 5. Temple University Hospital, Philadelphia. 6. Memorial Sloan-Kettering Cancer Center, New York. 7. Saint John's Health Center, Santa Monica. 8. Endocyte, Inc., Indianapolis. 9. Horizon Oncology Research, Lafayette, USA.
Abstract
BACKGROUND: This report examines (99m)Tc-etarfolatide imaging to identify the presence of folate receptor (FR) on tumors of women with recurrent/refractory ovarian or endometrial cancer and correlates expression with response to FR-targeted therapy (vintafolide). PATIENTS AND METHODS: In this phase II, single-arm, multicenter study, patients with advanced ovarian cancer were imaged with (99m)Tc-etarfolatide before vintafolide treatment. Up to 10 target lesions (TLs) were selected based on Response Evaluation Criteria In Solid Tumors criteria using computed tomography scans. Single-photon emission computed tomography images of TLs were assessed for (99m)Tc-etarfolatide uptake as either FR positive or negative. Patients were categorized by percentage of TLs positive and grouped as FR(100%), FR(10%-90%), and FR(0%). Lesion and patient response were correlated with etarfolatide uptake. RESULTS: Forty-nine patients were enrolled; 43 were available for analysis. One hundred thirty-nine lesions were (99m)Tc-etarfolatide evaluable: 110 FR positive and 29 FR negative. Lesion disease control rate (DCR = stable or response) was observed in 56.4% of FR-positive lesions versus 20.7% of FR-negative lesions (P < 0.001). Patient DCR was 57%, 36%, and 33% in FR(100%), FR(10%-90%), and FR(0%) patients, respectively. Median overall survival was 14.6, 9.6, and 3.0 months in FR(100%), FR(10%-90%), and FR(0%) patients, respectively. CONCLUSIONS: Overall response to FR-targeted therapy and DCR correlate with FR positivity demonstrated by (99m)Tc-etarfolatide imaging. CLINICAL TRIAL NUMBER: NCT00507741.
BACKGROUND: This report examines (99m)Tc-etarfolatide imaging to identify the presence of folate receptor (FR) on tumors of women with recurrent/refractory ovarian or endometrial cancer and correlates expression with response to FR-targeted therapy (vintafolide). PATIENTS AND METHODS: In this phase II, single-arm, multicenter study, patients with advanced ovarian cancer were imaged with (99m)Tc-etarfolatide before vintafolide treatment. Up to 10 target lesions (TLs) were selected based on Response Evaluation Criteria In Solid Tumors criteria using computed tomography scans. Single-photon emission computed tomography images of TLs were assessed for (99m)Tc-etarfolatide uptake as either FR positive or negative. Patients were categorized by percentage of TLs positive and grouped as FR(100%), FR(10%-90%), and FR(0%). Lesion and patient response were correlated with etarfolatide uptake. RESULTS: Forty-nine patients were enrolled; 43 were available for analysis. One hundred thirty-nine lesions were (99m)Tc-etarfolatide evaluable: 110 FR positive and 29 FR negative. Lesion disease control rate (DCR = stable or response) was observed in 56.4% of FR-positive lesions versus 20.7% of FR-negative lesions (P < 0.001). Patient DCR was 57%, 36%, and 33% in FR(100%), FR(10%-90%), and FR(0%) patients, respectively. Median overall survival was 14.6, 9.6, and 3.0 months in FR(100%), FR(10%-90%), and FR(0%) patients, respectively. CONCLUSIONS: Overall response to FR-targeted therapy and DCR correlate with FR positivity demonstrated by (99m)Tc-etarfolatide imaging. CLINICAL TRIAL NUMBER: NCT00507741.
Authors: Emily B Ehlerding; Carolina A Ferreira; Eduardo Aluicio-Sarduy; Dawei Jiang; Hye Jin Lee; Charles P Theuer; Jonathan W Engle; Weibo Cai Journal: Mol Pharm Date: 2018-05-30 Impact factor: 4.939
Authors: Swapnil S Desale; Kruti S Soni; Svetlana Romanova; Samuel M Cohen; Tatiana K Bronich Journal: J Control Release Date: 2015-09-14 Impact factor: 9.776
Authors: Joseph P Marshalek; Paul S Sheeran; Pier Ingram; Paul A Dayton; Russell S Witte; Terry O Matsunaga Journal: J Control Release Date: 2016-09-26 Impact factor: 9.776